Status: Enrolling
Investigator: Joseph Masdeu
Study Coordinator: Nilene Crisci
Phone: 713.441.3771
To clarify the role of inflammation in the pathogenesis of AD, it is important to measure inflammation in brain of people with AD and its relationship with abnormal tau, as the disease progresses. So far, there is no in vivo data in humans verif ... Read more >
Status: Enrolling
Investigator: Sheetal Shroff
Study Coordinator: KaDeesia Brown
Phone: 713.441.9120
In Amyotrophic Lateral Sclerosis (ALS), the reduction of regulatory T lymphocyte (Treg) numbers and suppressive function correlates with rapid disease progression. We completed a phase 1 study of infusions of expanded autologous Tregs in combina ... Read more >
Status: Enrolling
Investigator: Andrew Billnitzer
Study Coordinator: Valerie Flores
Phone: 713.363.9803
The purpose of this study is to compare the efficacy of Troriluzole (200mg once daily) versus placebo after 48 weeks of treatment in subjects with spinocerebellar ataxia (SCA). ... Read more >
Status: Enrolling
Investigator: Stanley Appel
Study Coordinator: Anjana Singh
Phone: 713.441.9120
The purpose of this protocol is to develop and maintain a biospecimen bank comprised of blood, urine, CSF collected during diagnostic evaluations, tissue from biopsies and autopsies collected from patients with neurological disease and non-neu ... Read more >
Status: Enrolling
Investigator: Jason Thonhoff
Study Coordinator: Anjana Singh
Phone: 713.441.9120
This leukapheresis study proposes to continue our work in developing and optimizing our Treg manufacturing process. Under this study, up to 10 patients with ALS will undergo leukapheresis. Their Tregs will subsequently be isolated and expand ... Read more >
Status: Open Not Enrolling
Investigator: Sherif Nagueh
Study Coordinator: Nirali Patel
Phone: 713.441.2116
Multicenter, Randomized, Double-blind, Parallel-group Extension to Study AC-058B201 to Investigate the Long-term Safety, Tolerability, and Efficacy of Three Doses of ACT-128800, an Oral S1P1 Receptor Agonist, in Patients With Relapsing-remitting ... Read more >
Status: Enrolling
Investigator: Maria Pascual
Study Coordinator: Victoria Arbones
Phone: 713.441.7650
The ARTFL LEFFTDS Longitudinal Frontotemporal Dementia (ALLFTD) study aims to evaluate sporadic (s-) and familial (f-) frontotemporal lobar degeneration (FTLD) patients and asymptomatic family members of f-FTLD patients, characterizing the cohor ... Read more >
Status: Enrolling
Investigator: Sheetal Shroff
Study Coordinator: KaDeesia Brown
Phone: 713.441.9120
The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS. ... Read more >
Status: Enrolling
Investigator: Ericka Greene
Study Coordinator: Anjana Singh
Phone: 713.441.9120
Complement component 5 (C5) inhibition therapies have been available for patients with generalized Myasthenia Gravis (gMG) in the United States since the introduction of Soliris® in late 2017. Alexion is developing potential new therapies that ... Read more >
Status: Open Not Enrolling
Investigator: Jun Li
Study Coordinator: Aramide Balogun
Phone: 713.441.6955
This study aims to look at the genetic differences between individuals with neurological disorders and healthy controls, and whether these genetic differences contribute to nerve conduction speeds. We expect that this study will identify a small ... Read more >
Status: Enrolling
Investigator: Joseph Masdeu
Study Coordinator: Nilene Crisci
Phone: 713.441.3771
The discovery of AD risk genes coding for proteins involved in inflammation has revived the interest in neuroinflammation (or brain inflammation) in the pathogenesis of AD. To understand the role of inflammation in the pathogenesis of AD, it is ... Read more >